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The Mediterranean diet is rich in fruits and vegetables and has been associated with a
variety of health beneﬁts including cancer prevention. One aspect of the diet that has
not received enough attention is Mediterranean herbs. Speciﬁcally, rosemary and its
polyphenolic diterpenes (carnosic acid and carnosol) are known to possess anti-oxidant
activity that may be beneﬁcial for cancer control. Herein, we describe the in vitro and in
vivo studies carried out towards understanding the molecular mechanisms of carnosic acid
and carnosol leading to inhibition of prostate cancer. The reported ﬁndings suggest that
these polyphenols target multiple signaling pathways involved in cell cycle modulation and
apoptosis. Further work is required to understand its potential for health promotion and
potential drug discovery for prostate cancer chemoprevention.
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MEDITERRANEAN DIET AND PROSTATE CANCER
The Mediterranean diet has received signiﬁcant attention for its
metabolic and cardiovascular health promoting beneﬁts (Piscopo,
2009). The traditional Mediterranean diet primarily consists of a
high intake of fresh fruits and vegetables, legumes, non-reﬁned
cereals including bread, ﬁsh, olive oil, a moderate consumption
of red wine, and a low consumption of red meats (Keys et al.,
1986). There have been multiple epidemiological studies eval-
uating various components of this diet. However, an area that
has not received enough attention is the use of culinary herbs
including rosemary, basil, oregano, sage, and others. One herb
in particular, rosemary (Rosmarinus ofﬁcinalis), has long been
associated with anti-inﬂammatory and anti-oxidant properties.
A population-based study has even suggested that an overall risk
reduction in cancer incidence is correlated with patients consum-
ing herbs including rosemary (OR = 0.66, 95% CI = 0.37–1.15;
Fortes et al., 2003).
Recently, the European Union (EU) has approved the use of
rosemary extracts for food preservation and has been adopted
into the EU food additive legislation (Aguilar et al., 2008). The
study was done using rosemary extracts standardized to carnosic
acid and carnosol, which have been noted for their strong anti-
oxidant activity. Multiple extracts have been evaluated for their
acute and chronic toxicity suggesting they are very tolerable. Acute
oral toxicity testing of a rosemary extract at doses as high as 8.5
and 10.5 g/kg in male and female rats, respectively, did not induce
mortality. In a 13-week oral study in male and female rats the
NOAEL (no observable adverse event level) of different rosemary
extracts was between 180 and 400 mg/kg body weight/day, which
was equivalent to 20–60 mg/kg/day of carnosol and carnosic acid
per day. The adult mean intake was estimated to be between 500
and 1,500 mg of carnosol and carnosic acid per day. The panel
concluded that the use of rosemary as a preservative/additive was
not a safety concern. In the United States, rosemary has also been
categorized by the FDA as “generally recognized as safe” or GRAS
(CFR182.10; 182.20).
Rosemary itself contains a variety of polyphenolic compounds
including carnosol, carnosic acid, methyl carnosol, rosmarinic
acid, ursolic acid, and many others (Lo et al., 2002). Approx-
imately 5% of the dry weight of rosemary leaves is comprised
of the phenolic diterpenes carnosol and carnosic acid (Huang
et al., 1994). They are estimated to account for >90% of the anti-
oxidant activity (Aruoma et al., 1992). Carnosic acid, which is the
most abundant diterpene, has been shown to be well absorbed
orally in rats (90 mg/kg) with a maximum serum concentration
of 126 μM and an absolute oral bioavailability of 65.1% (Pis-
copo, 2009). The anti-oxidant properties are seen through its
ability to chelate iron, scavenge peroxyl free radicals and inhibit
lipid peroxidation (-Dilas et al., 2012). Carnosol is a derivative of
carnosic acid containing a lactone ring. It has been known to
have anti-inﬂammatory, anti-oxidant, anti-microbial, and anti-
cancer properties. The other phytochemicals are also known to
possess similar properties. For example, rosmarinic acid has been
known to have strong radical scavenging effect (Aruoma et al.,
1992). Ursolic acid is a triterpenoid compound that has been
shown to have anti-inﬂammatory and even an anti-depressant
effect (Machado et al., 2012). Carnosol exhibits anti-inﬂammatory
properties through its ability to reduce leukotrienes, inhibit
5-lipoxygenase, antagonize the intracellular Ca2+ mobilization,
and inhibit the secretion of leukocyte elastase (Poeckel et al.,
2008). In traditional Chinese medicine, rosemary extracts which
contain a high amount of diterpenes and triterpenes have been
used to treat inﬂammatory conditions. Additionally, a variety
of dietary supplements of rosemary extracts are available that
have been standardized to carnosol and/or carnosic acid. The
clinical implications of these phytochemicals are far-reaching
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and still undergoing analysis including the treatment of different
cancers.
Prostate cancer is an example of a potential use of rosemary for
chemoprevention and tumor reduction. It is a good candidate for
chemoprevention because it is typically diagnosed in men over the
age of 50 suggesting that even a minimal delay in prostate cancer
development through pharmacological or nutritional manipula-
tion could greatly reduce the incidence of clinically detectable
disease (Johnson et al., 2008). Prostate cancer has a long latency
period and a tendency to metastasize via the blood stream (Joshua
et al., 2008; Schroder et al., 2009; Siegel et al., 2011). Autopsy stud-
ies have shown that many young men in their 20s and 30s have
developed pre-cancerous lesions (Yatani et al., 1982). Prostate can-
cer is a proliferation of epithelial cells which are seen to have a
chromosomal gain or loss mutation, leading to uncontrolled cell
growth. It is a slow growing cancer that follows the same progres-
sion as many epithelial cancers from mild dysplasia to invasion
of the basement membrane (Umar et al., 2012). There are three
classiﬁcations with the ﬁrst form being latent and benign, the
second form being moderately progressive and the third form
being rapidly progressive and extremely malignant (Waterbor and
Bueschen, 1995). The latest statistics amongmales in the USA esti-
mates about 240,890 new cancer cases and 33,720 mortalities due
to prostate cancer alone in 2011 (Siegel et al., 2011).
ANTI-CANCER ACTIVITY OF CARNOSIC ACID TOWARDS
PROSTATE CANCER
Carnosic acid, a natural diterpene, alone constitutes 1.5–2.5% of
dried leaves of rosemary. Well-known as one of the most potent
anti-oxidant agents of rosemary, carnosic acid also exhibits effec-
tive anti-cancer properties. It has signiﬁcant growth inhibitory and
cytotoxic properties in prostate cancer cell lines, DU-145 and PC3,
decreasing the cell viability of the cell lines to 13 and 20%, respec-
tively, when treated for 48 h at a concentration of 6.25 μg/ml (i.e.,
18.8 μM; Yesil-Celiktas et al., 2010).
Another study by Kar et al. (2012) also illustrates the anti-
proliferative and cytotoxic properties of carnosic acid in a concen-
tration and time-dependent manner in DU-145 and PC3 prostate
cancer cell lines as determined by MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay.
At a concentration of 80 μM (i.e., 26.6 μg/ml), carnosic acid
resulted in >95 and 90% cell death in PC3 and DU-145 cells,
respectively. The half maximal inhibitory concentration (IC50)
value for PC3 cells was found to be 41.1 μM. Carnosic acid
induced apoptosis as evidenced by DNA fragmentation, terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining and Annexin V–PI ﬂow cytometric analysis. At 80 μM,
carnosic acid promoted apoptosis in PC3 cells with 56.1% apopto-
sis compared to 47.2% apoptosis in DU-145 cells (Kar et al., 2012).
Carnosic acid also increased expression of the pro-apoptotic pro-
tein Bax and decreased the anti-apoptotic Bcl-2 protein leading
to the release of cytochrome c from the mitochondria sugges-
tive of a mitochondrial-dependent apoptosis. The modulation
of caspases by carnosic acid appears to be cell-type depen-
dent. Carnosic acid induces apoptosis through both pathways
in PC3 cells as seen by the upregulation of caspases-8, -9,
and -3 by 8.2-, 5.1-, and 10.1-fold after 36 h of treatment. Although
expression of caspase-9 increased by 9.3-fold in DU-145 cells, no
change in expression of caspase-8 was observed in these cells sug-
gesting activation of only intrinsic mediated apoptotic pathway
in androgen refractory DU-145 cell line. Furthermore, carnosic
acid was also found to trigger apoptosis via inhibition of phos-
phatidylinositide 3-kinase (PI3K)/Akt signaling pathway which in
turn suppresses IκB kinase/nuclear factor kappa B (IKK/NF-κB)
pathway in PC3 prostate cancer cells (Kar et al., 2012).
Besides prostate cancer, carnosic acid is also cytotoxic against
various cancer cell lines derived from human leukemia, breast,
lung, and liver malignant tissues (Yesil-Celiktas et al., 2010).
Some in vitro studies have shown the anti-cancer activities
of carnosic acid against human neuroblastoma IMR-32 cells
(Tsai et al., 2011), colonic adenocarcinoma Caco-2 cells (Visanji
et al., 2006), and myeloid leukemia HL-60 cells (Steiner et al.,
2001). A possible in vivo chemopreventive effect of carnosic
acid has been described in golden Syrian hamsters against 7,12-
dimethylbenz(a)anthracene (DMBA)-induced oral carcinogenesis
(Manoharan et al., 2010). At an oral dose of 10 mg/kg body
weight/day, carnosic acid almost completely prevented forma-
tion of oral carcinoma in hamster’s buccal mucosa compared
to 100% tumor formation in control animals. Levels of phase I
and phase II detoxiﬁcation enzymes were found to increase and
decrease in control hamsters, respectively, whereas levels of these
biomarkers were restored to normal ranges in carnosic acid treated
animals. Also, the level of anti-oxidant enzymes were reduced
in control group compared to the treated group. These results
suggest that inhibition of DMBA-induced oral cancer might be
due to anti-oxidant effect and removal of the toxic metabolite
of DMBA by carnosic acid (Manoharan et al., 2010).
ANTI-CANCER ACTIVITY OF CARNOSOL TOWARDS
PROSTATE CANCER
Carnosol is an ortho-diphenolic diterpenewith an abietane carbon
skeleton that is the product of oxidative degradation of carnosic
acid (Gajhede et al., 1990; Johnson, 2011). Together, carnosic acid
and carnosol are responsible for nearly all of the anti-oxidant activ-
ity of rosemary. Carnosol has been reported to possess numerous
pharmacological properties including anti-inﬂammatory, anti-
oxidant, and anti-tumor activities.
However, the anti-tumorigenic effects of carnosol on prostate
cancer have only recently been explored. Work in our laboratory
has demonstrated the anti-proliferative properties of carnosol in a
dose and time-dependent manner on PC3 cells with an observed
IC50 value of 48.3, 39.2, and 34 μmol/l at 24, 48, and 72 h,
respectively. Carnosol led to an induction of cell cycle arrest at G2
phase of the cell cycle in PC3 cells along with increase in expres-
sion levels of cell cycle regulatory proteins, p21 and p27, and a
simultaneous decrease in protein levels of cyclin-A, -D1, and -D2
and cyclin-dependent kinase (cdk) proteins-2 and -6 (Johnson
et al., 2008).
Our study further revealed how carnosol modulates multiple
signaling pathways in a single cell line. Concomitant with cell cycle
arrest, we also observed upregulation of Bax and downregulation
of Bcl-2 and pro-caspase 8 suggesting occurrence of apopto-
sis upon treatment of carnosol in PC3 cells. Besides activating
the intrinsic apoptotic pathway, carnosol also inhibited the
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PI3K/Akt pathway. At a dose of 20 and 40 μM, carnosol showed
a dramatic decrease in the protein expression of Akt at phos-
phorylation sites Thr-308 and Ser-473, respectively. In addition
to PI3K/Akt inhibition, carnosol also activated the 5′ adeno-
sine monophosphate-activated protein kinase (AMPK) pathway.
The expression of AMPK beta-1 regulatory subunit was found
to increase by 365% in carnosol treated cells compared to con-
trol cells via a protein array. AMPK and its downstream molecule
mammalian target of rapamycin (mTOR) have been considered as
a therapeutic target for cancer treatments. Typically mTOR pro-
tein is upregulated in prostate cancer. Upon treatment of PC3 cells
with carnosol we observed a dose-dependent decrease in phospho-
rylation of mTORprotein thereby leading to inhibition of prostate
cancer in vitro (Johnson et al., 2008).
Additionally, our in vivo studies have demonstrated that
carnosol when given orally at a dose of 30 mg/kg inhibits the
growth of prostate cancer in athymic nude mice by 36% along
with a 26% decrease in serum prostate-speciﬁc antigen (PSA) lev-
els compared to untreated control animals (Johnson et al., 2010).
This study also highlights a unique property of carnosol wherein
it functions as a dual disruptor of both androgen receptor (AR)
and estrogen receptor α (ERα) in vitro in prostate cancer cells
(LNCaP and 22Rv1) as well as in vivo in nude mice (Johnson
et al., 2010). Using a time-resolved ﬂuorescence resonance energy
transfer (TR-FRET) assay we found that carnosol can bind to both
AR and ERα and displays antagonist activity at both the recep-
tors without any agonistic properties associated with it. More
than 35 agents have been evaluated as dual disruptors of AR
and ERα, however, to the best of our knowledge, this is the
ﬁrst report of an agent that possesses solely antagonistic properties
(Wilkinson et al., 2008).
CONCLUSION
This review focuses on the Mediterranean herb, rosemary, its
polyphenolic diterpenes (carnosic acid and carnosol) and their
role in chemoprevention of prostate cancer. Epidemiological
studies suggest a reduced risk of cancer inpatients consuming rose-
mary. Herein, we have described themechanismbywhich carnosic
acid and carnosol inhibits prostate cancer. Essentially both diter-
penes inhibit cancer by promoting apoptosis and inhibiting the
critical PI3K/Akt signaling pathway which is an important reg-
ulator of tumor cell survival. These ﬁndings warrant further
research to understand the potential of rosemary as a cancer
chemopreventive agent in prostate cancer.
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